Latest Period
Q2 2026
Security Snapshot
Edgewise Therapeutics, Inc. - Common Stock, $0.0001 par value per share (EWTX) Institutional Ownership
CUSIP: 28036F105
13F Institutional Holders and Ownership History from Q1 2021 to Q2 2026
Institutions Reporting
226
Shares (Excl. Options)
119,194,438
Price
$40.63
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.0001 par value per share
- Symbol
- EWTX on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 119,194,438
- Total 13F value
- $4,822,487,808
- Portfolio coverage rank
- 0.01%
- Share change
- +498,622
- Value change
- +$51,387,100
- Number of holders
- 226
- Shares outstanding
- 107,531,105
- SEC-reported price per share
- $44.31
- Insider filing price
- $44.31
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- EWTX - Edgewise Therapeutics, Inc. - Common Stock, $0.0001 par value per share is tracked under CUSIP 28036F105.
- 226 institutions reported positions in Q2 2026.
- 9 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 212 to 226 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $3,721,351,792 to $4,822,487,808.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 226 institutions filings for Q2 2026.
Security key
28036F105
Latest holder period
Q2 2026
13F holders
226
13D/G owners
9
CIK / CUSIP context first
Open Q2 2026 holders
EWTX full holder history
Edgewise Therapeutics, Inc. SEC filings
Edgewise Therapeutics, Inc. company facts
Edgewise Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 28036F105:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
9
Security
EWTX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 14% | $234,894,152 | 15,252,867 | ORBIMED ADVISORS LLC | 09 May 2025 | |||
| Paradigm Biocapital Advisors LP | 9.5% | +55% | $493,917,249 | +$177,649,746 | 10,215,455 | +56% | Paradigm BioCapital Advisors LP | 30 Jun 2026 |
| RA CAPITAL MANAGEMENT, L.P. | 7.8% | -21% | $405,788,496 | -$98,426,433 | 8,392,730 | -20% | RA Capital Management, L.P. | 30 Jun 2026 |
| JANUS HENDERSON GROUP PLC | 5.5% | +16% | $197,165,481 | +$31,204,379 | 5,915,556 | +19% | JANUS HENDERSON GROUP PLC | 31 Mar 2026 |
| BlackRock, Inc. | 5.5% | $76,363,411 | 5,824,866 | BlackRock, Inc. | 30 Jun 2025 | |||
| FMR LLC | 5.1% | $265,399,677 | 5,489,135 | FMR LLC | 30 Jun 2026 | |||
| Novo Holdings A/S | 4.9% | $168,525,535 | 5,350,000 | Novo Holdings A/S | 23 Apr 2026 | |||
| PERCEPTIVE ADVISORS LLC | 4.4% | -28% | $60,458,535 | -$22,875,429 | 4,639,949 | -27% | Perceptive Advisors LLC | 30 Jun 2025 |
| BAKER BROS. ADVISORS LP | 3.4% | -50% | $178,978,114 | -$174,264,085 | 3,701,719 | -49% | Baker Bros. Advisors LP | 30 Jun 2026 |
As of 30 Jun 2026, 226 institutional investors reported holding 119,194,438 shares of Edgewise Therapeutics, Inc. - Common Stock, $0.0001 par value per share (EWTX). This represents 111% of the company’s total 107,531,105 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
93%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 14% | 15,518,492 | 0% | 12% | $630,516,330 |
| Paradigm Biocapital Advisors LP | 9.5% | 10,215,455 | +39% | 7.8% | $415,053,937 |
| RA CAPITAL MANAGEMENT, L.P. | 7.8% | 8,392,730 | -20% | 3% | $340,996,620 |
| BlackRock, Inc. | 6.1% | 6,606,336 | +2.1% | 0% | $268,415,431 |
| Jupiter Topco LLC | 5.6% | 6,075,331 | 0% | 0.1% | $246,945,299 |
| FMR LLC | 5.1% | 5,489,135 | +440% | 0.01% | $223,023,556 |
| NOVO HOLDINGS A/S | 5% | 5,350,000 | 0% | 13% | $217,370,500 |
| Driehaus Capital Management LLC | 4.4% | 4,728,623 | +5.6% | 1.1% | $192,123,952 |
| PERCEPTIVE ADVISORS LLC | 4.1% | 4,373,974 | -1.1% | 2.8% | $177,714,564 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.6% | 3,860,670 | +1.9% | 0% | $156,859,022 |
| BAKER BROS. ADVISORS LP | 3.4% | 3,701,719 | -44% | 0.75% | $150,400,843 |
| Siren, L.L.C. | 3% | 3,184,629 | -28% | 2.6% | $129,391,476 |
| Cormorant Asset Management, LP | 2.3% | 2,510,000 | -23% | 5.2% | $101,981,300 |
| GEODE CAPITAL MANAGEMENT, LLC | 2% | 2,174,051 | +21% | 0% | $88,348,054 |
| ALLIANCEBERNSTEIN L.P. | 2% | 2,119,024 | +23% | 0.02% | $66,749,256 |
| Integral Health Asset Management, LLC | 1.9% | 2,000,000 | +25% | 3.3% | $81,260,000 |
| BRAIDWELL LP | 1.9% | 1,996,965 | -15% | 3% | $81,136,688 |
| MORGAN STANLEY | 1.8% | 1,948,597 | -13% | 0% | $79,171,495 |
| STATE STREET CORP | 1.7% | 1,827,927 | +6.5% | 0% | $74,268,674 |
| MPM BIOIMPACT LLC | 1.5% | 1,620,780 | -2.4% | 4% | $65,852,291 |
| BANK OF AMERICA CORP /DE/ | 1.4% | 1,558,260 | +17% | 0% | $63,312,105 |
| Qube Research & Technologies Ltd | 1.2% | 1,252,507 | +52% | 0.06% | $50,889,359 |
| DIMENSIONAL FUND ADVISORS LP | 1.1% | 1,139,726 | -6.6% | 0.01% | $46,309,097 |
| AMERICAN CENTURY COMPANIES INC | 1% | 1,127,078 | -1.8% | 0.02% | $45,793,233 |
| First Light Asset Management, LLC | 1% | 1,095,171 | +9.3% | 2.7% | $44,496,798 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
22
Latest
Q2 2026
Rows shown
1-22 of 22
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 119,194,438 | $4,822,487,808 | +$51,387,100 | $40.63 | 226 |
| 2026 Q1 | 118,515,156 | $3,721,351,792 | -$100,536,601 | $31.50 | 212 |
| 2025 Q4 | 121,825,813 | $3,022,606,371 | +$263,739,414 | $24.82 | 199 |
| 2025 Q3 | 111,964,035 | $1,816,272,411 | -$102,066,033 | $16.22 | 172 |
| 2025 Q2 | 118,737,861 | $1,557,153,070 | +$135,315,946 | $13.11 | 177 |
| 2025 Q1 | 105,289,941 | $2,320,227,206 | +$130,326,516 | $22.00 | 190 |
| 2024 Q4 | 98,918,436 | $2,640,722,866 | -$78,891,260 | $26.70 | 197 |
| 2024 Q3 | 101,289,495 | $2,703,865,523 | -$12,073,061 | $26.69 | 174 |
| 2024 Q2 | 101,617,706 | $1,830,101,707 | +$179,027,088 | $18.01 | 138 |
| 2024 Q1 | 91,602,360 | $1,670,777,013 | +$311,144,088 | $18.24 | 126 |
| 2023 Q4 | 79,647,397 | $871,350,413 | +$122,344,417 | $10.94 | 115 |
| 2023 Q3 | 68,438,296 | $392,172,292 | -$8,215,044 | $5.73 | 84 |
| 2023 Q2 | 69,494,963 | $538,802,876 | +$23,832,932 | $7.75 | 94 |
| 2023 Q1 | 66,455,672 | $443,090,314 | -$748,812 | $6.67 | 85 |
| 2022 Q4 | 66,466,915 | $594,208,237 | +$17,736,112 | $8.94 | 90 |
| 2022 Q3 | 64,390,889 | $633,608,275 | +$132,537,303 | $9.84 | 92 |
| 2022 Q2 | 50,965,041 | $405,682,841 | -$30,249,561 | $7.96 | 76 |
| 2022 Q1 | 53,964,373 | $523,513,727 | +$33,997,944 | $9.70 | 71 |
| 2021 Q4 | 50,239,434 | $767,640,710 | +$33,441,771 | $15.28 | 56 |
| 2021 Q3 | 48,038,152 | $795,758,000 | +$3,108,242 | $16.60 | 47 |
| 2021 Q2 | 46,323,514 | $984,550,000 | +$40,348,386 | $21.33 | 45 |
| 2021 Q1 | 45,681,359 | $1,477,378,000 | +$1,477,377,994 | $32.50 | 31 |